Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 13/20 | 0.43 |
| ▸ | ITGA5 | P08648 | 13/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 13/20 | 0.43 |
| ▸ | ITGAV | P06756 | 13/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6645991 | 0.91 | CHRNB2 (0.44) | ITGB1ITGA5ITGB3ITGAVTP53 | |
| SCHEMBL6830856 | 0.88 | CHRNB2 (0.46) | ITGB1ITGA5ITGB3ITGAVTP53 | |
| SCHEMBL6645393 | 0.88 | ITGB1 (0.46) | ITGB1ITGA5TP53TAS1R3TAS1R1 | |
| SCHEMBL6644987 | 0.83 | CHRNB2 (0.45) | ITGB1ITGA5ITGB3ITGAVTP53 | |
| SCHEMBL6644545 | 0.83 | CHRNB2 (0.46) | ITGB1ITGA5ITGB3ITGAVTP53 | |
| SCHEMBL6826089 | 0.82 | TAS1R3 (0.44) | TP53TAS1R3TAS1R1PPARG | |
| SCHEMBL6490416 | 0.81 | CHRNB2 (0.43) | ITGB1ITGA5ITGB3ITGAVCHRNB2 | |
| SCHEMBL6646509 | 0.79 | ITGB1 (0.43) | ITGB1ITGA5TP53 | |
| SCHEMBL6646068 | 0.77 | ITGB3 (0.41) | ITGB1ITGA5ITGB3ITGAVTP53 | |
| SCHEMBL6645478 | 0.77 | SORT1 (0.42) | TP53SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040133008-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133008-A1 | Amide compounds | APOB, APOL1, LDLR | ITGB1 711/4885ITGA5 3235/4885ITGB3 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.